Receptor tyrosine kinase expression in high‑grade gliomas before and after chemoradiotherapy

Wang,Kuanyu; Huang,Ruoyu; Wu,Chenxing; Li,Guanzhang; Zhao,Zheng; Hu,Huimin; Liu,Yanwei

doi:10.3892/ol.2019.11017

Receptor tyrosine kinase expression in high‑grade gliomas before and after chemoradiotherapy

Authors:
- Kuanyu Wang
- Ruoyu Huang
- Chenxing Wu
- Guanzhang Li
- Zheng Zhao
- Huimin Hu
- Yanwei Liu
View Affiliations

Affiliations: Department of Gamma Knife Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, P.R. China, Department of Neurosurgery, Beijing Neurosurgical Institute, Beijing 100050, P.R. China, Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing 100050, P.R. China, Department of Neuropathology, Beijing Neurosurgical Institute, Beijing 100050, P.R. China, Department of Radiotherapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: October 29, 2019 https://doi.org/10.3892/ol.2019.11017
Pages: 6509-6515
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is the most common type of malignant brain tumor, and is characterized by invasive growth and chemoradiotherapy resistance. The following Cancer Genome Atlas mutation subtypes were identified in initial high‑grade gliomas and recurrent gliomas treated by chemoradiotherapy: Isocitrate dehydrogenase 1/2 (IDH1/2) mutation, epidermal growth factor receptor variant III (EGFRvIII) mutation, tumor protein P53 mutation, PTEN mutation, O6‑methylguanine‑DNA methyltransferase promoter methylation and telomerase reverse transcriptase (TERT) mutation. The expression profile of 58 receptor tyrosine kinases (RTKs) were also examined. It was revealed that the proneural tumor subtype and IDH1/2 mutation are more frequent in recurrent tumors compared with initial tumors. Lower frequencies of the classical subtype, EGFRvIII mutation and TERT mutation were identified in recurrent tumors. A set of six RTK genes in which the level of expression was influenced by chemoradiotherapy was identified. Survival analysis revealed that the expression of several RTKs, including apoptosis‑associated tyrosine kinase, fibroblast growth factor receptor 1 and insulin‑like growth factor 1 receptor (IGF1R), was associated with patient survival. The stimulation of glioma cells by IGF1 in vitro was found to decreased the viability of the cells following treatment with temozolomide (TMZ). In addition, the expression level of IGF1R was increased in glioma cells treated with TMZ. These data suggest that altered RTK expression levels may influence the sensitivity of glioma to chemoradiotherapy.

View Figures

View References

1	Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L, et al: CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 375:263–273. 2016. View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
3	Stupp R, Brada M, van den Bent MJ, Tonn JC and Pentheroudakis G; ESMO Guidelines Working Group, : High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25 (Suppl):iii93–iii101. 2014. View Article : Google Scholar : PubMed/NCBI
4	Cancer Genome Atlas Research Network, ; Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, et al: Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. New Engl J Med. 372:2481–2498. 2015. View Article : Google Scholar : PubMed/NCBI
5	Mock A, Geisenberger C, Orlik C, Warta R, Schwager C, Jungk C, Dutruel C, Geiselhart L, Weichenhan D, Zucknick M, et al: LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. Int J Cancer. 139:424–432. 2016. View Article : Google Scholar : PubMed/NCBI
6	Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, et al: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483:479–483. 2012. View Article : Google Scholar : PubMed/NCBI
7	Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W and Mehta M: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol. 31:337–343. 2013. View Article : Google Scholar : PubMed/NCBI
8	Intergroup Radiation Therapy Oncology Group Trial 1942, ; Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup radiation therapy oncology group trial 9402. J Clin Oncol. 24:2707–2714. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, et al: Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 68:1831–1836. 2007. View Article : Google Scholar : PubMed/NCBI
10	Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, et al: Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 333:1453–1455. 2011. View Article : Google Scholar : PubMed/NCBI
11	Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, et al: Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 226:7–16. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
13	Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI
14	Regad T: Targeting RTK signaling pathways in cancer. Cancers(Basel). 7:1758–1784. 2015.PubMed/NCBI
15	Sundaram MV: RTK/Ras/MAPK signaling. WormBook. 1–19. 2006.PubMed/NCBI
16	Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
17	Ou SH, Soo RA, Kubo A, Kawaguchi T and Ahn MJ: Will the requirement by the US FDA to simultaneously Co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally? Front Oncol. 4:582014. View Article : Google Scholar : PubMed/NCBI
18	Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, et al: Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 22:262–269. 2016. View Article : Google Scholar : PubMed/NCBI
19	Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, et al: Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci USA. 109:570–575. 2016. View Article : Google Scholar
20	Liu Y, Hu H, Wang K, Zhang C, Wang Y, Yao K, Yang P, Han L, Kang C, Zhang W and Jiang T: Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas. Oncotarget. 5:12593–12606. 2014.PubMed/NCBI
21	Cartland SP, Genner SW, Zahoor A and Kavurma MM: Comparative evaluation of TRAIL, FGF-2 and VEGF-A-induced angiogenesis in vitro and in vivo. Int J Mol Sci. 17(pii): E20252016. View Article : Google Scholar : PubMed/NCBI
22	Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, et al: High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One. 4:e72732009. View Article : Google Scholar : PubMed/NCBI
23	Zhou Y, Li S, Li J, Wang D and Li Q: Effect of microRNA-135a on cell proliferation, migration, invasion, apoptosis and tumor angiogenesis through the IGF-1/PI3K/Akt signaling pathway in non-small cell lung cancer. Cell Physiol Biochem. 42:1431–1446. 2017. View Article : Google Scholar : PubMed/NCBI
24	Liang Z, Diepstra A, Xu C, van Imhoff G, Plattel W, Van Den Berg A and Visser L: Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma. PLoS One. 9:e874742014. View Article : Google Scholar : PubMed/NCBI
25	Mountzios G, Aivazi D, Kostopoulos I, Kourea HP, Kouvatseas G, Timotheadou E, Zebekakis P, Efstratiou I, Gogas H, Vamvouka C, et al: Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. PLoS One. 9:e914072014. View Article : Google Scholar : PubMed/NCBI
26	Almiron Bonnin DA, Ran C, Havrda MC, Liu H, Hitoshi Y, Zhang Z, Cheng C, Ung M and Israel MA: Insulin-mediated signaling facilitates resistance to PDGFR inhibition in proneural hPDGFB-driven gliomas. Mol Cancer Ther. 16:705–716. 2017. View Article : Google Scholar : PubMed/NCBI
27	Wang H, Tang C, Na M, Ma W, Jiang Z, Gu Y, Ma G, Ge H, Shen H and Lin Z: miR-422a inhibits glioma proliferation and invasion by targeting IGF1 and IGF1R. Oncol Res. 25:187–194. 2017. View Article : Google Scholar : PubMed/NCBI
28	Arun S, Vanisree AJ and Ravisankar S: Connexin 30 downregulates Insulin-like growth factor receptor-1, abolishes Erk and potentiates effects of an IGF-R inhibitor in a glioma cell line. Brain Res. 1643:80–90. 2016. View Article : Google Scholar : PubMed/NCBI
29	Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN and Wang J: InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma. Clin Cancer Res. 22:1767–1776. 2016. View Article : Google Scholar : PubMed/NCBI
30	Jiang J, Wang W, Fang D, Jin X, Ding L and Sun X: MicroRNA-186 targets IGF-1R and exerts tumor-suppressing functions in glioma. Mol Med Rep. 16:7821–7828. 2017. View Article : Google Scholar : PubMed/NCBI